The extra lives saved between 2010 and 2018 means that the NHS has met its own ambitious 20% target two years ahead of the 2020 deadline.
News
COVID-19: Updates from Mologic, Gilead, CEPI
With the outbreak at “critical juncture”, analysts are saying Gilead’s remdesivir stands a 50% chance of success as a vaccine.
£200m mental health crisis services rolled out across England
Another £140 million will then be used to bolster the services further from 2021 onwards.
97% of UK pharmacists expect ‘great pressure’ in 2020
Key issues mentioned were complex working processes between pharmacies and GP practices, handling prescriptions and management of patient records.
Imfinzi cancer combo falls short in DANUBE trial
Despite the setback, AstraZeneca says that it “remains committed to addressing unmet needs in bladder cancer.”
Post-surgery chemo halves risk of recurring rare kidney cancer
71% of patients given chemotherapy survived for three years or more after joining the trial without their disease coming back, compared with 46% of patients who were on surveillance.
NICE pushes Doptelet for pre-surgery liver disease treatment
Last year, the therapy received a positive opinion from the EMA’s CHMP.
Sanofi, Babylon link-up to tackle digestive health
Only an estimated 30% of people in the UK who suffer from IBS have actually been diagnosed and, of those, 61% often mistreat their symptoms with analgesics or antacids.
Givlaari approved in EU following recent CHMP nudge
The drug is a first-of-its kind injectable RNAi therapeutic.
Orphan drugs face “uphill battle” in 2020
EMA-assigned Orphan Drug Designations declined 49% between 2014 and 2019.
COVID-19: Takeda, Arcturus, Veeva all chip in
The UK has reported its biggest overnight jump in cases, bringing the total to 87 infected patients.
2020 International Clinical Researcher of the Year postponed until September
The 2020 International Clinical Researcher of the Year competition has been postponed until the end of September/beginning of October.
Four pharma companies found guilty of anti-competitive behaviour
Ultimately, the CMA is fining King and Accord-UK £75,573 and £1,882,238 respectively, with Accord-UK and Auden agreeing to make a £1 million payment to the NHS.
App to determine risk of preterm birth developed
When babies are born early, before 37 weeks of pregnancy, they are more likely to die, or have physical, developmental and emotional problems.
First patient dosed in potential lymphoedema treatment trial
The drug being evaluated is an oral, small molecule drug candidate known as deupirfenidone.
